No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD.
OBJECTIVE To investigate the effects of propionyl l-carnitine ( PLC ) on clinical and functional parameters , and markers of the overall oxidation state in patients with peripheral arterial disease ( PAD ) associated with non-insulin-dependent diabetes mellitus ( NIDDM ) . DESIGN AND SETTING R and omised , double-blind , clinical trial , conducted in the Unit of Medical Angiology of the University of Catania . PATIENTS AND INTERVENTIONS Seventy-four patients with NIDDM-associated PAD were treated with PLC ( 2 g/day ) or placebo for 12 months . MAIN OUTCOME MEASURES Ankle/brachial index ( ABI ) and the distance of pain-free walking were evaluated at baseline , 6 and 12 months . Malondialdehyde , 4-hydroxynonenal , oxidation time of low-density lipoproteins , and nitrite/nitrate ratio were measured as indices of the overall oxidation profiles at baseline and 12 months . RESULTS In the PLC group , ABI progressively increased ( 0.78 , 0.83 , and 0.88 at 0 , 6 and 12 months , respectively ) . The distance of pain-free walking also improved ( 366.4 , 441.9 and 519.8 m , respectively ) . In the placebo group , these parameters were relatively unchanged . Significant improvements in all parameters of the oxidative profile were seen in the PLC-treated group , with only minor variations observed in the placebo group . CONCLUSIONS These results suggest that adjunct therapy with PLC may be warranted in type 2 diabetes-associated PAD
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .